### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 3 April 2003 (03.04.2003)

PCT

(10) International Publication Number WO 03/027076 A3

- (51) International Patent Classification<sup>7</sup>: A61K 31/4164, C07D 233/90, C07C 257/18, C07D 401/04, 403/04, 405/12, 403/12
- (21) International Application Number: PCT/EP02/10434
- (22) International Filing Date:

17 September 2002 (17.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 01203851.9 21

21 September 2001 (21.09.2001) EP

- (71) Applicant (for all designated States except US): SOLVAY PHARMACEUTICALS B.V. [NL/NL]; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KRUSE, Cornelis, G. [NL/NL]; Solvay Pharmaceuticals B.V., c/o C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). LANGE, Josephus, H.M. [NL/NL]; Solvay Pharmaceuticals B.V., c/o C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). HERREMANS, Arnoldus, H.J. [NL/NL]; Solvay Pharmaceuticals B.V., c/o C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). VAN STUIVENBERG, Herman, H. [NL/NL]; Solvay Pharmaceuticals B.V., c/o C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).

- (74) Agent: MUIS, Maarten; OCTROOIBUREAU ZOAN B.V., P.O. Box 140, NL-1380 AC Weesp (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, Cl, CM, GΛ, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:


with international search report

(88) Date of publication of the international search report: 20 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

V

(54) Title: 1H-IMIDAZOLE DERIVATIVES HAVING CB<sub>1</sub> AGONISTIC, CB<sub>1</sub> PARTIAL AGONISTIC OR CB<sub>1</sub>- ANTAGONISTIC ACTIVITY



(57) Abstract: AbstractThe present invention relates to a group of novel 1H-imidazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component. These 1H-imidazole derivatives are potent cannabinoid-CB1 receptor agonists, partial agonists or antagonists, useful for the treatment of psychiatric and neurological disorders, as well as and other diseases involving cannabinoid neurotransmission. The compounds have the general formula (I) wherein R and R1-R4 have the meanings given in the specification.

PCT/EP 02/10434

ÎPC	· · · · · · · · · · · · · · · · · · ·	7C257/18 C07D401/04 C0	02/10434
	CO7D405/12 CO7D403/12	7C257/18 C07D401/04 C0	7D403/04
Accordin	g to International Patent Classification (IPC) or to both national	Classification and IDO	
O FIELD	DS SEARCHED		~
IPC 7	o documentation searched (classification system followed by d	assification symbols)	
1	COTO COTO ACIA		· .
Documen	Italian saamhod other the	<u> </u>	
}	itation searched other than minimum documentation to the exte	int that such documents are included in the fields	searched
1			
PETLO	data base consulted during the international search (name of	data base and, where practical, search terms use	nd)
DETES	TEIN Data, WPI Data, PAJ, CHEM AE	BS Data, EPO-Internal	•
1			
<u> </u>			
	ENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of	the relevant passages	Poles de la constant
V			Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 133,	no. 18,	6.0
	30 October 2000 (2000-10-30) Columbus, Ohio, US;	•	6,8
1	abstract no. 252124		
]	LI, ZHI FANG ET AL. "Faction	Synthesis of	
		refrance de de como de la como de	
1	coupling of nitriles with azob promoted by samarium diiodide	enzene	
	VL005180028		1
	see compound wherein R is 2,4- abstract	diCTPh	Ì
	& CHIN. CHEM. LETT (2000) 11	(6)	
	495–498,	(6),	
		1	
		_/	
		-/	
1			
ĺ	`		1.
V Furthe	f documents on Table 11 to		
	r documents are listed in the continuation of box C.	Patent family members are listed in	annex
	gories of cited documents :	"T" later document out the control	
Consider	defining the general state of the art which is not ed to be of particular relevance	"T" tater document published after the internal or priority date and not in conflict with the cited to understand the principle or theor invention	utional filing date application but
eartier dod filing date	Sument but published on or after the International	invention  "X" document of particular relevance; the claim cannot be considered possible.	
'L" document which is	which may throw doubts on priority claim(s) or cited to establish the publication date of another	cannot be considered novel or cannot be involve an inventive step when the document	ned invention considered to
O* document	referring to an oral disclosure, area, autority	cannot be considered to investe the clain	ned invention
P* document	Of this had prior to 45	document is combined with one or more ments, such combination being obtained.	tive step when the
	and broadly dette creatings	in the art.  *&* document member of the same patent fam	
tate of the act	ual completion of the international search	Date of mailing of the international search	
4 D	ecember 2002		
	ing address of the ISA	11/12/2002	
	European Patent Crico P.B. 5818 County	Authorized officer	
	Tel. (+31-70) 340-2010 Tv 31 651 0-0-1	1	
	T &C (+31-70) 340-3018	Scruton-Evans, I	
·~: 1/.SA/210 (:	second cheel) ( bits 1000)		

PCT/EP 02/10434

		PCT/EP 02/10434
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Calegory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAISEI UEDA ET AL: "A novel ring transformation of 5-Acylaminouracils" TETRAHEDRON LETTERS, vol. 29, no. 36, 1988, pages 4607-4610, XP001038533 see Compound 3e	
<b>A</b>	NORIAKI KUDO ET AL: "Synthesis and Herbicidal activity of 1,5-Diarylpyrazole derivatives" CHEM PHARM BULL, vol. 47, no. 6, 1999, pages 857-868, XP001026111	1
Y	cited in the application see compounds 7,8,29a,29b	7
A	KHANNA I K ET AL: "1,2-DIARYLIMIDAZOLES AS POTENT, CYCLOOXYGENASE-2 SELECTIVE, AND ORALLY ACTIVE ANTIINFLAMMATORY AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, 1997, pages 1634-1647, XP000941303 ISSN: 0022-2623 cited in the application see table 7	1-10
<b>Y</b>	ISH KHANNA ET AL: "Selective Cyclooxygenase 2-Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 16, 2000, pages 3168-3185, XP001026112 cited in the application See Scheme 9	4-8
(	PERTWEE R G: "PHARMACOLOGY OF CANNABINOID RECEPTOR LIGANDS"  CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 8, August 1999 (1999-08), pages 635-664, XP000923352 ISSN: 0929-8673 see compounds on page 641 and pages 657-659	1-10
'	US 5 616 601 A (KHANNA ISH ET AL) 1 April 1997 (1997-04-01) see especially formula 4, column 22	7
	WO 00 63204 A (NOVARTIS ERFIND VERWALT GMBH; NOVARTIS AG (CH); REVESZ LASZLO (CH)) 26 October 2000 (2000-10-26) the whole document	1-10
İ	-/	ļ

Form PCT/ISA/210 (continuation of second sheet) (July 192)

PCT/EP 02/10434

Category *	tation) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/EP 02/10434
- Lichory	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 46209 A (SANOFI SYNTHELABO ;BARTH FRANCIS (FR); CAMUS PHILIPPE (FR); MARTIN) 10 August 2000 (2000-08-10) the whole document	1-10
Y	THOMAS ET AL: "Comparative receptor binding analyses of cannabinoid agonists and antagonists" J PHARMACOL. EXP THER, vol. 285, no. 1, 1998, pages 285-292, XP000942485 see whole document	1-10
		·
	× .	
SAZIO (contir	nuction of second cheet) (July 1932)	

International application No. PCT/EP 02/10434

### INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 1-3,9,10 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  See FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3,9,10

Present claims 1-3,9,10 relate to a compound or use defined by reference to a desirable characteristic or property, namely that it be a prodrug of the formula I compounds.

The claims cover all compounds and uses having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds and uses. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the the claimed scope impossible. Consequently, the search over the whole of out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds of formula I and their use, and not their prodrugs.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

PCT/EP 02/10434

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5616601	A	01-04-1997	AT	224374 T	15-10-2002
			AU	3202595 A	22-02-1996
			CA	2195845 A1	08-02-1996
			DE	69528273 D1	24-10-2002
			EP	0772600 A1	14-05-1997
			JP	10503211 T	24-03-1998
			WO	9603388 A1	08-02-1996
WO 0063204		26-10-2000	AU	4295300 A	02-11-2000
		•	BR	0010598 A	05-02-2002
			CN	1378544 T	06-11-2002
			CZ	20013696 A3	13-02-2002
		•	WO	0063204 A2	26-10-2000
			EΡ	1224180 A2	24-07-2002
			NO	20014987 A	14-12-2001
			SK	14562001 A3	05-03-2002
			TR	200102967 T2	21-01-2002
			US	2002049220 A1	25-04-2002
WO 0046209	A	10-08-2000	FR	2789078 A1	04-08-2000
			FR	2789079 A1	04-08-2000
		,	AU	2298900 A	25-08-2000
		•	BG	105749 A	28-02-2002
			BR	0007895 A	30-10-2001
			CN	1346349 T	24-04-2002
			CZ	20012697 A3	17-10-2001
			EE	200100399 A	15-10-2002
			ΕP	1150961 A1	07-11-2001
		,	WO	0046209 A1	10-08-2000
			HR	20010564 A1	31-08-2002
			JP	2002536366 T	29-10-2002
			NO	20013736 A	28-09-2001
			NZ	512886 A	25-10-2002
			PL	350030 A1	21-10-2002
			SK	10872001 A3	03-12-2001
		•	TR	200102054 T2	21-05-2002
			US	6432984 B1	13-08-2002

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)

•